Compounds > 5'-o-(n-(alanyl)sulfamoyl)adenosine
Page last updated: 2024-12-08

5'-o-(n-(alanyl)sulfamoyl)adenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5'-O-(N-(alanyl)sulfamoyl)adenosine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID196672
CHEMBL ID1163065
SCHEMBL ID4320823
MeSH IDM0194255

Synonyms (22)

Synonym
unii-48gg0u2x78
48gg0u2x78 ,
112921-04-7
A5A ,
5'-o-(n-(alanyl)sulfamoyl)adenosine
ala-sa
alasa
DB03376
SCHEMBL4320823
CHEMBL1163065
[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl n-[(2s)-2-aminopropanoyl]sulfamate
5'-o-(n-(l-alanyl)-sulfamoyl)adenosine
db-03376
adenosine, 5'-(n-((2s)-2-amino-1-oxopropyl)sulfamate)
adenosine, 5'-(((2s)-2-amino-1-oxopropyl)sulfamate)
bdbm50197291
5'-o-(l-alanylsulfamoyl)adenosine
DTXSID60920952
9-{5-o-[(2-amino-1-hydroxypropylidene)sulfamoyl]pentofuranosyl}-9h-purin-6-amine
Q27259144
((2r,3s,4r,5r)-5-(6-amino-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl ((s)-2-aminopropanoyl)sulfamate
5/'-o-(n-(alanyl)sulfamoyl)adenosine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Yersiniabactin biosynthetic proteinYersinia pestisIC50 (µMol)1.15001.15001.15001.1500AID1322281
Yersiniabactin biosynthetic proteinYersinia pestisKi2.50002.50002.50002.5000AID1322283
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki2.50000.00000.929610.0000AID1322283
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki2.50000.00000.970810.0000AID1322283
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki2.50000.00000.937510.0000AID1322283
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID412493Antibacterial activity against wild type Escherichia coli at 30 nmol after 16 to 20 hrs2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID1322286Drug uptake in Mycobacterium smegmatis ATCC 700084 at 100 uM by LC-MS/Ms analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes.
AID1322285Drug uptake in Escherichia coli ATCC 25922 at 100 uM by LC-MS/Ms analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes.
AID412491Antibacterial activity against Staphylococcus aureus ATCC 25923 at 30 nmol after 16 to 20 hrs2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID408604Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
AID412494Antibacterial activity against Escherichia coli delta ABN mutant lacking peptidase A, B, N at 30 nmol after 16 to 20 hrs2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID1322284Drug uptake in Bacillus subtilis ATCC 6051 at 100 uM by LC-MS/Ms analysis2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes.
AID412492Antibacterial activity against Enterococcus faecalis ATCC 29212 at 30 nmol after 16 to 20 hrs2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Antibacterial 5'-O-(N-dipeptidyl)-sulfamoyladenosines.
AID408613Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.1 uM2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
AID408606Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.5 uM2008Journal of medicinal chemistry, May-22, Volume: 51, Issue:10
Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
AID1322282Inhibition of aminoacyl tRNA synthetase in T7 coupled rabbit reticulocyte lysate assessed as reduction in transcription/translation of luciferase template DNA propagated in Escherichia coli DH5alpha after 90 mins2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes.
AID1322281Inhibition of recombinant Yersinia pestis C-terminal His6-tagged HMWP2 cysteine adenylation domain (1 to 1491 residues) expressed in Escherichia coli BL21(DE3) using 7-Methyl-6-thioguanosine as substrate preincubated for 10 mins followed by L-cysteine add2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes.
AID1322283Inhibition of recombinant Yersinia pestis C-terminal His6-tagged HMWP2 cysteine adenylation domain (1 to 1491 residues) expressed in Escherichia coli BL21(DE3) after 15 mins in presence of L-cysteine by ATP-[32P]-pyrophosphate exchange assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.79 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alanine
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.. alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.		2.730alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid		EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.0210glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
adenosine
quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit		2.730adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
mupirocin
Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.		2.4520alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol		antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		2.0410homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
sirolimus
Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.		2.0410antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol		antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials